Molecular Therapy — Nucleic Acids · 2015 · 80 citations · 42 references
MedicineOncologyPharmacologyChemotherapyMolecular OncologyMolecular PharmacologyLigand BindingNucleic Acid DeliveryNucleic Acid Drug DesignOligonucleotide DeliveryOncology PharmacologyAptamer StructureAptamer Targeting LigandsAptamer-based TargetingAptamersCell Surface Recognition ReceptorsNf-κb SignalingRna Aptamer BindingRna Aptamers
Aptamers able to bind efficiently cell-surface receptors differentially expressed in tumor and in healthy cells are emerging as powerful tools to perform targeted anticancer therapy. Here, we present a novel oligonucleotide chimera, composed by an RNA aptamer and a DNA decoy. Our assembly is able to (i) target tumor cells via an antitransferrin receptor RNA aptamer and (ii) perform selective codelivery of a chemotherapeutic drug (Doxorubicin) and of an inhibitor of a cell-survival factor, the nuclear factor κB decoy oligonucleotide. Both payloads are released under conditions found in endolysosomal compartments (low pH and reductive environment). Targeting and cytotoxicity of the oligonucleotidic chimera were assessed by confocal microscopy, cell viability, and Western blot analysis. These data indicated that the nuclear factor κB decoy does inhibit nuclear factor κB activity and ultimately leads to an increased therapeutic efficacy of Doxorubicin selectively in tumor cells.
42
In vitro selection of RNA molecules that bind specific ligands
Andrew D. Ellington, Jack W. Szostak · Nature · 1990 · 9.7K citations
I. Vermes, C. Haanen, H M Steffens-Nakken et al. · Journal of Immunological Methods · 1995 · 5.4K citations · Full text
NUPACK: Analysis and design of nucleic acid systems
Joseph N. Zadeh, Conrad Steenberg, Justin S. Bois et al. · Journal of Computational Chemistry · 2010 · 1.8K citations · Full text